Drug intelligence / Profile preview

SPED

Development stage
Preclinical
Administration
Oral, Intravenous, Intranasal, Rectal, Intramuscular, Subcutaneous
01

Overview

SPED (rhamnan-type sulfated polysaccharide derivative) is a novel marine-derived candidate being developed as a hypoglycemic agent for type 2 diabetes. It is prepared from a sulfated polysaccharide (SPE) derived from *Enteromorpha prolifera* through specific enzymatic hydrolysis. SPED has demonstrated the ability to improve glucose metabolism and promote the PI3K/PKB/GSK-3β signaling pathway by regulating the mRNA expression of insulin receptors (IR), insulin receptor substrate 2 (IRS-2), phosphatidylinositol 3 kinase (PI3K), protein kinase B (PKB), and glycogen synthase kinase 3β (GSK-3β). Acute and sub-acute toxicity studies in mice showed no damaging effects, indicating a favorable safety profile.

02

Targets

GSK3 (Glycogen synthase kinase 3 beta)INSR (Insulin receptor)IRS2 (Insulin receptor substrate 2)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)AKT (RAC-alpha serine/threonine-protein kinase)

Beyond the preview

Go deeper on SPED.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPED.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call